News

REYKJAVIK, Iceland and LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
REYKJAVIK, Iceland and LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leading biopharmaceutical company with a market capitalization of $62.17 billion, finds itself at a critical juncture as it navigates challenges to its ...
The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...
The company's former top-selling treatment, Eylea, is losing ground to biosimilar competition. Luckily, a next-generation version, Eylea HD, is picking up some of the slack. First-quarter Eylea HD ...